Utilize este identificador para referenciar este registo:
https://hdl.handle.net/1822/74411
Título: | Epigallocatechin-3-gallate PEGylated poly(lactic-co-glycolic) acid nanoparticles mitigate striatal pathology and motor deficits in 3-nitropropionic acid intoxicated mice |
Autor(es): | Cano, Amanda Ettcheto, Miren Espina, Marta Auladell, Carmen Folch, Jaume Kühne, Britta A Barenys, Marta Sánchez-López, Elena Souto, Eliana B. García, Maria Luisa Turowski, Patric Camins, Antonio |
Palavras-chave: | 3-nitropropionic acide pigallocatechin-3-gallate Huntingtons disease neurodegenerative diseases PLGA-PEG polymeric nanoparticles 3-nitropropionic acid epigallocatechin-3-gallate |
Data: | 2020 |
Editora: | Future Medicine |
Revista: | Nanomedicine |
Citação: | Cano, Amanda; Ettcheto, Miren; Espina, Marta; Auladell, Carmen; Folch, Jaume; Kühne, Britta A; Barenys, Marta; Sánchez-López, Elena; Souto, Eliana; García, Maria Luisa; Turowski, Patric; Camins, Antonio, Epigallocatechin-3-gallate PEGylated poly(lactic-co-glycolic) acid nanoparticles mitigate striatal pathology and motor deficits in 3-nitropropionic acid intoxicated mice. Nanomedicine, 16(1), 19-35, 2020. |
Resumo(s): | Aim: To compare free and nanoparticle (NP)-encapsulated epigallocatechin-3-gallate (EGCG) for the treatment of Huntingtons disease (HD)-like symptoms in mice. Materials \& methods: EGCG was incorporated into PEGylated poly(lactic-co-glycolic) acid NPs with ascorbic acid (AA). HD-like striatal lesions and motor deficit were induced in mice by 3-nitropropionic acid-intoxication. EGCG and EGCG/AA NPs were co-administered and behavioral motor assessments and striatal histology performed after 5 days. Results: EGCG/AA NPs were significantly more effective than free EGCG in reducing motor disturbances and depression-like behavior associated with 3-nitropropionic acid toxicity. EGCG/AA NPs treatment also mitigated neuroinflammation and prevented neuronal loss. Conclusion: NP encapsulation enhances therapeutic robustness of EGCG in this model of HD symptomatology. Together with our previous findings, this highlights the potential of EGCG/AA NPs in the symptomatic treatment of neurodegenerative diseases. |
Tipo: | Artigo |
URI: | https://hdl.handle.net/1822/74411 |
DOI: | 10.2217/nnm-2020-0239 |
ISSN: | 1743-5889 |
Versão da editora: | https://www.futuremedicine.com/journal/nnm |
Arbitragem científica: | yes |
Acesso: | Acesso restrito UMinho |
Aparece nas coleções: | CEB - Publicações em Revistas/Séries Internacionais / Publications in International Journals/Series |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
document_54116_1.pdf Acesso restrito! | 1,59 MB | Adobe PDF | Ver/Abrir |